Perspectives for applying Alphaviruses in antitumor therapy
- Authors: Nazarenko A.S.1, Biryukova Y.K.1, Kolyasnikova N.M1, Vorovich M.F.1,2, Pestov N.B.1, Ishmukhametov A.A.1,2
-
Affiliations:
- M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences (Polio Institute)
- Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russian Federation (Sechenov University)
- Issue: Vol 13, No 4 (2023)
- Pages: 627-641
- Section: REVIEWS
- URL: https://journals.rcsi.science/2220-7619/article/view/158869
- DOI: https://doi.org/10.15789/2220-7619-PFA-12111
- ID: 158869
Cite item
Full Text
Abstract
Oncolytic viral therapy is a promising approach for treating tumors. Oncolytic viruses can directly lyse tumor cells and indirectly activate antitumor immunity. Alphaviruses, as oncolytic viruses, are particularly promising agents because they can selectively infect and lyse tumor cells, modulate microtumor environment, elicit immune-mediated lysis of tumor cells, and serve as a platform for transgene delivery. To ensure safety, attenuated strains of Alphaviruses are typically used for genetic engineering, and immunogenic tumor-associated antigens or cytokines are commonly chosen as transgenes. Studies evaluating both in vitro and in vivo oncolytic and immunomodulatory effects of Alphaviruses and vectors based on them have been growing exponentially. Animal models of various tumor types were used to examine the effectiveness of Alphaviruses, including Sindbis, Semliki Forest virus, Geta (strain M1), Venezuelan equine encephalitis virus, and vectors based on them. Additionally, Alphaviruses revealed enhanced antitumor activity while used in combination therapies with other oncolytic viruses. Alphavirus-like replicon particles based on attenuated Venezuelan equine encephalitis virus may serve for transgene delivery to express heterologous proteins at high levels, and induce both humoral and cellular immune responses. An alphaviral vector-based vaccine, encoding the HER2 extracellular and transmembrane domains, has demonstrated safety and efficacy in preclinical mouse models, as well as in phase I clinical trials for advanced breast cancer patients with HER2 overexpression. This vaccine is known to be safe, effective, and capable of inducing T-cell immunity. In this review, we discuss the current progress in preclinical and clinical investigations, as well as the future potential of Alphaviruses for oncolytic virotherapy.
Full Text
##article.viewOnOriginalSite##About the authors
Alina S. Nazarenko
M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences (Polio Institute)
Author for correspondence.
Email: nazarenko_as@chumakovs.su
SPIN-code: 8733-3345
Researcher, Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides
Russian Federation, 108819, Moscow, Settlement “Moskovskiy”, Village of Institute of Poliomyelitis, Premises 8, build. 1Yulia K. Biryukova
M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences (Polio Institute)
Email: biriukova-ula@mail.ru
ORCID iD: 0000-0002-5804-4001
SPIN-code: 7940-9531
Scopus Author ID: 36028326200
ResearcherId: D-8577-2014
PhD (Biology), Senior Researcher, Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development
Russian Federation, 108819, Moscow, Settlement “Moskovskiy”, Village of Institute of Poliomyelitis, Premises 8, build. 1Nadezhda M Kolyasnikova
M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences (Polio Institute)
Email: kolyasnikova_nm@chumakovs.su
PhD (Medicine), Leading Researcher, Head of Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides
Russian Federation, 108819, Moscow, Settlement “Moskovskiy”, Village of Institute of Poliomyelitis, Premises 8, build. 1Mikhail F. Vorovich
M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences (Polio Institute); Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russian Federation (Sechenov University)
Email: vorovich_mf@chumakovs.su
PhD (Biology), Leading Researcher, Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development, Associate Professor, Department of Organization and Research of Immunobiological Technologies
Russian Federation, 108819, Moscow, Settlement “Moskovskiy”, Village of Institute of Poliomyelitis, Premises 8, build. 1; 119991, Moscow, st Trubetskaya 8/2Nikolai B. Pestov
M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences (Polio Institute)
Email: pestov_nb@chumakovs.su
PhD (Chemistry), Leading Researcher, Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides
Russian Federation, 108819, Moscow, Settlement “Moskovskiy”, Village of Institute of Poliomyelitis, Premises 8, build. 1Aidar A. Ishmukhametov
M.P. Chumakov Federal Scientific Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences (Polio Institute); Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russian Federation (Sechenov University)
Email: ishmukhametov@chumakovs.su
SPIN-code: 2971-8228
Scopus Author ID: 57195034442
RAS Full Member, DSc (Medicine), Professor, General Director, Head of the Department of Organization and Research of Immunobiological Technologies
Russian Federation, 108819, Moscow, Settlement “Moskovskiy”, Village of Institute of Poliomyelitis, Premises 8, build. 1; 119991, Moscow, st Trubetskaya 8/2
References
- Alberts P., Tilgase A., Rasa A., Bandere K., Venskus D. The advent of oncolytic virotherapy in oncology: The Rigvir® story. Eur. J. Pharmacol., 2018, vol. 837, pp. 117–126. doi: 10.1016/j.ejphar.2018.08.042
- Al-Saleh W., Delvenne P., Brule F.A., Menard S., Boniver J., Castronovo V. Expression of the 67 KD laminin receptor in human cervical preneoplastic and neoplastic squamous epithelial lesions: an immunohistochemical study. J. Pathol. Clin. Res., 1997, vol. 181, pp. 287–293. doi: 10.1002/(SICI)1096-9896(199703)181:3<287::AID-PATH762>3.0.CO;2-W
- Bradish C.J., Allner K., Maber H.B. The virulence of original and derived strains of Semliki Forest virus for mice, guinea-pigs and rabbits. J. Gen. Virol., 1971, vol. 12, pp. 141–160. doi: 10.1099/0022-1317-12-2-141
- Cassetti M.C., McElhiney S.P., Shahabi V., Pullen J.K., Le Poole I.C., Eiben G.L., Smith L.R., Kast W.M. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine, 2004, vol. 22, pp. 520–527. doi: 10.1016/j.vaccine.2003.07.003
- Crosby E.J., Gwin W., Blackwell K., Marcom P.K., Chang S., Maecker H.T., Broadwater G., Hyslop T., Kim S., Rogatko A., Lubkov V., Snyder J.C., Osada T., Hobeika A.C., Morse M.A., Lyerly H.K., Hartman Z.C. Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study. Clin. Cancer Res., 2019, vol. 25, pp. 2725–2736. doi: 10.1158/1078-0432.CCR-18-3102
- Frampton J.E. Teserpaturev/G47Δ: first approval. BioDrugs, 2022, vol. 36, pp. 667–672. doi: 10.1007/s40259-022-00553-7
- Fukunaga Y., Kumanomido T., Kamada M. Getah virus as an equine pathogen. Vet. Clin. North Am. Equine Pract., 2000, vol. 16, pp. 605–617. doi: 10.1016/s0749-0739(17)30099-8
- Gnjatic S., Nishikawa H., Jungbluth A.A., Güre A.O., Ritter G., Jäger E., Knuth A., Chen Y.-T., Old L.J. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res., 2006, vol. 95, pp. 1–30. doi: 10.1016/S0065-230X(06)95001-5
- Granot T., Venticinque L., Tseng J.-C., Meruelo D. Activation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectors. PLoS One, 2011, vol. 6: e20598. doi: 10.1371/journal.pone.0020598
- Granot T., Yamanashi Y., Meruelo D. Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity. Mol. Ther., 2014, vol. 22, pp. 112–122. doi: 10.1038/mt.2013.215
- Hasanzadeh M., Shadjou N., Lin Y., de la Guardia M. Nanomaterials for use in immunosensing of carcinoembryonic antigen (CEA): recent advances. Trends Analyt. Chem., 2017, vol. 86, pp. 185–205. doi: 10.1016/j.trac.2016.11.003
- Heikkilä J.E., Vähä-Koskela M.J.V., Ruotsalainen J.J., Martikainen M.W., Stanford M.M., McCart J.A., Bell J.C., Hinkkanen A.E. Intravenously administered Alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One, 2010, vol. 5: e8603. doi: 10.1371/journal.pone.0008603
- Hu J., Cai X.F., Yan G. Alphavirus M1 induces apoptosis of malignant glioma cells via downregulation and nucleolar translocation of p21WAF1/CIP1 protein. Cell Cycle, 2009, vol. 8, pp. 3328–3339. doi: 10.4161/cc.8.20.9832
- Huang P.Y., Guo J.H., Hwang L.H. Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol. Ther., 2012, vol. 20, pp. 298–305. doi: 10.1038/mt.2011.245
- Kaufman H.L., Kohlhapp F.J., Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov., 2015, vol. 14, pp. 642–662. doi: 10.1038/nrd4663
- Kaufman H.L., Shalhout S.Z., Iodice G. Talimogene laherparepvec: moving from first-in-class to best-in-class. Front. Mol. Biosci., 2022, vol. 9: 834841. doi: 10.3389/fmolb.2022.834841
- Kelly E., Russell S.J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther., 2007, vol. 15, pp. 651–659. doi: 10.1038/sj.mt.6300108
- Ketola A., Hinkkanen A., Yongabi F., Furu P., Määttä A.M., Liimatainen T., Pirinen R., Björn M., Hakkarainen T., Mäkinen K., Wahlfors J., Pellinen R. Oncolytic Semliki Forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res., 2008, vol. 68, pp. 8342–8350. doi: 10.1158/0008-5472.CAN-08-0251
- Klimstra W.B., Nangle E.M., Smith M.S., Yurochko A.D., Ryman K.D. DC-SIGN and L-SIGN can act as attachment receptors for Alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J. Virol., 2003, vol. 77, pp. 12022–12032. doi: 10.1128/jvi.77.22.12022-12032.2003
- Laine M., Luukkainen R., Toivanen A. Sindbis viruses and other Alphaviruses as cause of human arthritic disease. J. Int. Med., 2004, vol. 256, pp. 457–471. doi: 10.1111/j.1365-2796.2004.01413.x
- Leung J.Y.-S., Ng M.M.-L., Chu J.J.-H. Replication of Alphaviruses: a review on the entry process of Alphaviruses into cells. Adv. Virol., 2011, vol. 2011: e249640. doi: 10.1155/2011/249640
- Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr. Cancer Drug Targets, 2018, vol. 18, pp. 171–176. doi: 10.2174/1568009618666171129221503
- Lin Y., Zhang H., Liang J., Li K., Zhu W., Fu L., Wang F., Zheng X., Shi H., Wu S., Xiao X., Chen L., Tang L., Yan M., Yang X., Tan Y., Qiu P., Huang Y., Yin W., Su X., Hu H., Hu J., Yan G. Identification and characterization of Alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc. Natl Acad. Sci. USA, 2014, vol. 111, pp. e4504–e4512. doi: 10.1073/pnas.1408759111
- Määttä A.-M., Liimatainen T., Wahlfors T., Wirth T., Vähä-Koskela M., Jansson L., Valonen P., Häkkinen K., Rautsi O., Pellinen R., Mäkinen K., Hakumäki J., Hinkkanen A., Wahlfors J. Evaluation of cancer virotherapy with attenuated replicative Semliki Forest virus in different rodent tumor models. Int. J. Cancer, 2007, vol. 121, pp. 863–870. doi: 10.1002/ijc.22758
- Määttä A.-M., Mäkinen K., Ketola A., Liimatainen T., Yongabi F.N., Vähä-Koskela M., Pirinen R., Rautsi O., Pellinen R., Hinkkanen A., Wahlfors J. Replication competent Semliki Forest virus prolongs survival in experimental lung cancer. Int. J. Cancer, 2008, vol. 123, pp. 1704–1711. doi: 10.1002/ijc.23646
- Malfitano A.M., Di Somma S., Iannuzzi C.A., Pentimalli F., Portella G. Virotherapy: from single agents to combinatorial treatments. Biochem. Pharmacol., 2020, vol. 177: e113986. doi: 10.1016/j.bcp.2020.113986
- Markoff L. Alphaviruses (Chikungunya, Eastern Equine Encephalitis). In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Elsevier, Inc., 2020. Chapter 151: 1997-2006.e4
- Martikainen M., Niittykoski M., von und zu Fraunberg M., Immonen A., Koponen S., van Geenen M., Vähä-Koskela M., Ylösmäki E., Jääskeläinen J.E., Saksela K., Hinkkanen A. MicroRNA-attenuated clone of virulent Semliki Forest virus overcomes antiviral type I interferon in resistant mouse CT-2A glioma. J. Virol., 2015, vol. 89, pp. 10637–10647. doi: 10.1128/JVI.01868-15
- Martikainen M., Ramachandran M., Lugano R., Ma J., Martikainen M.-M., Dimberg A., Yu D., Merits A., Essand M. IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma. Mol. Ther. Oncolytics, 2021, vol. 21, pp. 37–46. doi: 10.1016/j.omto.2021.03.008
- Martikainen M., Ruotsalainen J., Tuomela J., Härkönen P., Essand M., Heikkilä J., Hinkkanen A. Oncolytic Alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice. Br. J. Cancer, 2017, vol. 117, pp. 51–55. doi: 10.1038/bjc.2017.151
- Morse M.A., Hobeika A., Gwin W., Osada T., Gelles J., Rushing C., Niedzwiecki D., Lyerly H.K. Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients. J. Immunother. Cancer, 2015, vol. 3: 444. doi: 10.1186/2051-1426-3-S2-P444
- Osada T., Berglund P., Morse M.A., Hubby B., Lewis W., Niedzwiecki D., Yang X.Y., Hobeika A., Burnett B., Devi G.R., Clay T.M., Smith J., Kim Lyerly H. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. Cancer Immunol. Immunother., 2012, vol. 61, pp. 1941–1951. doi: 10.1007/s00262-012-1248-y
- Quetglas J.I., Fioravanti J., Ardaiz N., Medina-Echeverz J., Baraibar I., Prieto J., Smerdou C., Berraondo P. A Semliki Forest virus vector engineered to express IFNα induces efficient elimination of established tumors. Gene Ther., 2012, vol. 19, pp. 271–278. doi: 10.1038/gt.2011.99
- Ramsey J., Mukhopadhyay S. Disentangling the frames, the state of research on the Alphavirus 6K and TF proteins. Viruses, 2017, vol. 9: 228. doi: 10.3390/v9080228
- Roche F.P., Sheahan B.J., O’Mara S.M., Atkins G.J. Semliki Forest virus-mediated gene therapy of the RG2 rat glioma. Neuropathol. Appl. Neurobiol., 2010, vol. 36, pp. 648–660. doi: 10.1111/j.1365-2990.2010.01110.x
- Rodriguez-Madoz J.R., Liu K.H., Quetglas J.I., Ruiz-Guillen M., Otano I., Crettaz J., Butler S.D., Bellezza C.A., Dykes N.L., Tennant B.C., Prieto J., González-Aseguinolaza G., Smerdou C., Menne S. Semliki Forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma. J. Virol., 2009, vol. 83, pp. 12266–12278. doi: 10.1128/JVI.01597-09
- Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev., 2001, vol. 14, pp. 778–809. doi: 10.1128/CMR.14.4.778-809.2001
- Scherwitzl I., Hurtado A., Pierce C.M., Vogt S., Pampeno C., Meruelo D. Systemically administered sindbis virus in combination with immune checkpoint blockade induces curative anti-tumor immunity. Mol. Ther. Oncolytics., 2018, vol. 9, pp. 51–63. doi: 10.1016/j.omto.2018.04.004
- Scherwitzl I., Opp S., Hurtado A.M., Pampeno C., Loomis C., Kannan K., Yu M., Meruelo D. Sindbis virus with anti-OX40 overcomes the immunosuppressive tumor microenvironment of low-immunogenic tumors. Mol. Ther. Oncolytics., 2020, vol. 17, pp. 431–447. doi: 10.1016/j.omto.2020.04.012
- Skidmore A.M., Bradfute S.B. The life cycle of the Alphaviruses: from an antiviral perspective. Antiviral Res., 2023, vol. 209: e105476. doi: 10.1016/j.antiviral.2022.105476
- Smit J.M., Waarts B.-L., Kimata K., Klimstra W.B., Bittman R., Wilschut J. Adaptation of Alphaviruses to heparan sulfate: interaction of Sindbis and Semliki Forest viruses with liposomes containing lipid-conjugated heparin. J. Virol., 2002, vol. 76, pp. 10128–10137. doi: 10.1128/jvi.76.20.10128-10137.2002
- Strauss J.H., Strauss E.G. The Alphaviruses: gene expression, replication, and evolution. Microbiol. Rev., 1994, vol. 58, pp. 491–562. doi: 10.1128/mr.58.3.491-562.1994
- Strauss J.H., Strauss E.G. Virus evolution: how does an enveloped virus make a regular structure? Cell, 2001, vol. 105, pp. 5–8. doi: 10.1016/s0092-8674(01)00291-4
- Sun S., Liu Y., He C., Hu W., Liu W., Huang X., Wu J., Xie F., Chen C., Wang J., Lin Y., Zhu W., Yan G., Cai J., Li S. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Cancer Lett., 2021, vol. 502, pp. 9–24. doi: 10.1016/j.canlet.2020.12.018
- Suomalainen M., Liljeström P., Garoff H. Spike protein-nucleocapsid interactions drive the budding of Alphaviruses. J. Virol., 1992, vol. 66, pp. 4737–4747. doi: 10.1128/JVI.66.8.4737-4747.1992
- Takenouchi A., Saito K., Saito E., Saito T., Hishiki T., Matsunaga T., Isegawa N., Yoshida H., Ohnuma N., Shirasawa H. Oncolytic viral therapy for neuroblastoma cells with Sindbis virus AR339 strain. Pediatr. Surg. Int., 2015, vol. 31, pp. 1151–1159. doi: 10.1007/s00383-015-3784-y
- Tian Y., Xie D., Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct. Target Ther., 2022, vol. 7: 117. doi: 10.1038/s41392-022-00951-x
- Tseng J.-C., Hurtado A., Yee H., Levin B., Boivin C., Benet M., Blank S.V., Pellicer A., Meruelo D. Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res., 2004, vol. 64, pp. 6684–6692. doi: 10.1158/0008-5472.CAN-04-1924
- Tseng J.-C., Levin B., Hirano T., Yee H., Pampeno C., Meruelo D. In vivo antitumor activity of sindbis viral vectors. J. Natl Cancer Inst., 2002, vol. 94, pp. 1790–1802. doi: 10.1093/jnci/94.23.1790
- Tseng J.-C., Levin B., Hurtado A., Yee H., de Castro I.P., Jimenez M., Shamamian P., Jin R., Novick R.P., Pellicer A., Meruelo D. Systemic tumor targeting and killing by Sindbis viral vectors. Nat. Biotechnol., 2004, vol. 22, pp. 70–77. doi: 10.1038/nbt917
- Unno Y., Shino Y., Kondo F., Igarashi N., Wang G., Shimura R., Yamaguchi T., Asano T., Saisho H., Sekiya S., Shirasawa H. Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin. Cancer Res., 2005, vol. 11, pp. 4553–4560. doi: 10.1158/1078-0432.CCR-04-2610
- Vähä-Koskela M.J.V., Kallio J.P., Jansson L.C., Heikkilä J.E., Zakhartchenko V.A., Kallajoki M.A. Kähäri V.-M., Hinkkanen A.E. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res., 2006, vol. 66, pp. 7185–7194. doi: 10.1158/0008-5472.CAN-05-2214
- Vähä-Koskela M.J.V., Le Boeuf F., Lemay C., De Silva N., Diallo J.-S., Cox J., Becker M., Choi Y., Ananth A., Sellers C., Breton S., Roy D., Falls T., Brun J., Hemminki A., Hinkkanen A., Bell J.C. Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. J. Virol., 2013, vol. 87, pp. 2363–2366. doi: 10.1128/JVI.01609-12
- Van den Brûle F.A., Castronovo V., Ménard S., Giavazzi R., Marzola M., Belotti D., Taraboletti G. Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. Eur. J. Cancer, 1996, vol. 32, no. 9, pp. 1598–1602. doi: 10.1016/0959-8049(96)00119-0
- Wang K.S., Kuhn R.J., Strauss E.G., Ou S., Strauss J.H. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J. Virol., 1992, vol. 66, pp. 4992–5001. doi: 10.1128/JVI.66.8.4992-5001.1992
- Wen J.-S., Zhao W.-Z., Liu J.-W., Zhou H., Tao J.-P., Yan H.-J., Liang Y., Zhou J.-J., Jiang L.-F. Genomic analysis of a Chinese isolate of Getah-like virus and its phylogenetic relationship with other Alphaviruses. Virus Genes, 2007, vol. 35, pp. 597–603. doi: 10.1007/s11262-007-0110-3
- Wollmann G., Tattersall P., van den Pol A.N. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J. Virol., 2005, vol. 79, pp. 6005–6022. doi: 10.1128/JVI.79.10.6005-6022.2005
- Yu M., Scherwitzl I., Opp S., Tsirigos A., Meruelo D. Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody. J. Immunother. Cancer, 2019, vol. 7, no. 1: 185. doi: 10.1186/s40425-019-0664-3
- Zhang H., Lin Y., Li K., Liang J., Xiao X., Cai J., Tan Y., Xing F., Mai J., Li Y., Chen W., Sheng L., Gu J., Zhu W., Yin W., Qiu P., Su X., Lu B., Tian X., Liu J., Lu W., Dou Y., Huang Y., Hu B., Kang Z., Gao G., Mao Z., Cheng S.-Y., Lu L., Bai X.-T., Gong S., Yan G., Hu J. Naturally existing oncolytic virus M1 is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections. Human Gene Ther., 2016, vol. 27, no. 9, pp. 700–711. doi: 10.1089/hum.2016.038
- Zhang J., Liu Y., Tan J., Zhang Y., Wong C.-W., Lin Z., Liu X., Sander M., Yang X., Liang L., Song D., Dan J., Zhou Y., Cai J., Lin Y., Liang J., Hu J., Yan G., Zhu W. Necroptotic virotherapy of oncolytic Alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC. Oncogene, 2021, vol. 40, no. 29, pp. 4783–4795. doi: 10.1038/s41388-021-01869-4
- Zhang S., Rabkin S.D. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? Expert Opin. Drug Discov., 2021, vol. 16, no. 4, pp. 391–410. doi: 10.1080/17460441.2021.1850689
- Zhang Y.-Q., Tsai Y.-C., Monie A., Wu T.-C., Hung C.-F. Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol. Ther., 2010, vol. 18, pp. 692–699. doi: 10.1038/mt.2009.318
- Zhao H., Garoff H. Role of cell surface spikes in Alphavirus budding. J. Virol., 1992, vol. 66, pp. 7089–7095. doi: 10.1128/JVI.66.12.7089-7095.1992
- Zimmerman O., Holmes A.C., Kafai N.M., Adams L.J., Diamond M.S. Entry receptors — the gateway to Alphavirus infection. J. Clin. Invest., 2023, vol. 133, no. 2: e165307. doi: 10.1172/JCI165307